Friday, August 3, 2012

The Fed and the ECB, or Lessons on Using a Pocket Bazooka

It is now clear to me that Euroland (love that moniker Mr. Gross, but I don't agree that the cult of equity is dying) and the Fed have one thing in common.  Over the past year they have decided to influence markets with language rather than action.  Let us not forget that while the current tactics of inaction and blabber may be similar now,  over the past five years the central banks' tactics have been very different.  In the face of great crisis, the Fed and Treasury -with a gun pointed at their heads in the form of market collapse- took decisive action by rapidly expanding the Fed's balance sheet by more that $1.5 trillion dollars over a couple months whilst simultaneously lowering rates to 0-.25%.  As a result the Fed eliminated the economic safety net in order to soften the crisis fallout and jump start the recovery.  While they succeeded at the former, the latter was less than successful.  However, it cannot be said that they fiddled while Rome burned.  I don't think the same can be said of the ECB.

At this point, the EU has not experience the action forcing event that we saw in the U.S. in 2007-2008, but their actions to date dealing with the drop-in-the-bucket size economies of Greece and Spain (with all due respect, of course) do not give me confidence that they are willing or able to step in if need be.  Thus far "actions" have been political.  Markets have traded on whispers and weak follow through.  Whilst this does not effect my long-term holdings, I am squeamishness that if a large event -credit or liquidity- hits Euroland they will not be capable of taking action.  THIS TYPE OF CRISIS WOULD NOT BE A BLACK SWAN.

So, I now look for ways to protect portfolio value against a market correction or collapse stemming from Euroland folly.  The worry is that inaction by the ECB in a crisis and a lack of Fed tools to absorb the event in U.S. markets leads to large drops in markets across the board.  So, my current homework is to identify market and technical indicators that I can use to signal those times when it is time to put on protection (since having protection consistently will consistently reduce profits). 

Monday, July 2, 2012

NKE is a BUY!!

I was not planning on making any moves as the weekend approached. Rather I was content to sit on my four open long positions (BRK.B, KMR, KO, CVS) and enjoy the weekend. But then I received an alert that NKE had broken $94.  It fell 10% overnight, between Thursday and Wednesday, on an earnings miss of 14.6% for Q4 and FY earnings results.  So here is a readout of my analysis and action.  Bottom line...I am glad this was on the watch list and that I know the company, because this is a great opportunity.


EPS Summary


  • $25 million charge related to the restructuring of its business in Europe
  • Increased spending on marketing by 23% QOQ (Olympics/NFL jersey contract/World Cup)
Revenue was up 12% to $6.5bn (missing projection - so what) and up 16% for the full year to $24.1bn, with increases across all product sectors with the U.S. market leading the way (not the greatest news). While there was revenue growth in China ($667mm) NKE sees growth moderating and will need to clear some inventory additional inventory from the region.


The real issue is that the gross margin declined by 1.5% in Q4 and 2.2% in the full year due to high product costs and investment in digital business. Net income declined by 8% largely due to the above one-time events.

Thesis
It is the first time since the last two years that NKE missed estimates. The company saw slowing growth in China in the last quarter, with orders coming in at 2%, which were expected to be somewhere in the range of 10%-15%. Overall, the announced results were disappointing weighing down on the company's stock. However, I maintain a positive outlook for the NKE as it has consistently shown growth in its earnings for a number of years, with strong revenue growth. It has also consistently beaten analysts' estimates in the past, which is why the current miss has come as a shock to many.  Moreover, one-off charges related to its European division and marketing costs related to the summer Olympics led to the recent decline in quarterly earnings. It has a strong business model with strong financials and a worldwide presence, and I expect it to do well going forward.  Despite the stock losing value in the past three months, it has outperformed over a one-year period. It currently trades close to its 52-week low of $77, which is a good entry point as the negative earnings results have been priced in.

Action and Forecast
I picked shares at $88.56 per share.  While this is not a trade, I do expect to see rebound by Monday (there was but not as big as I thought) with the stock likely trading up 3-5 points.  For the long-term, NKE is still the company that is was at the time of my last complete analysis (April).  It has ZERO debt, is the industry leader with a proven track record, and has some very positive events on the horizon (Olympics, World Cup, NFL Season as title jersey sponsor).  While I think that it will take 18-24 months for NKE to test its recent levels of $115, especially with global headwinds, I see this earnings release as a good opportunity to lock in a large margin of safety on the purchase of this company.

Wednesday, June 20, 2012

All Fed Up?

Looks like TWIST and not QE.  


So, the Fed is doing something to address what they see as an economy growing "less quickly that it normally would" without exhausting all their tools.  The Fed’s now forecasts an unemployment rate between 8% and 8.2% this year — basically, no improvement from June’s level of 8.2%.  

The Fed indicated that the housing market remains depressed and noted that global financial strains are also weighing on economic growth...not the most novel of observations.



What does this mean for the Fed's balance sheet (something the media generally ignores and focuses on the rhetoric)?  After three months of contraction (from expiration), we should once again see sudden growth from the new TWIST.  This action will keep the balance sheet at the $2.9-$3 trillion level for the next year.  That is a large sheet my any measure.

While the economic news is not good, this provides value investors additional time to hunt for deals (that is me!).  Expect stock market volumes to remain low.  The largest worry for me is still corporate revenues.  How will continued global economic slowing effect my models?  More later.

Quick and dirty analysis on KO.

I have not checked these numbers yet, but I do believe in the KO as a very good value buy.

From Seeking Alpha: 


Coca-Cola Still Looking Good, Merits 'Strong Buy'
June 20, 2012
by: Takeover Analyst
| about: KO, includes: DPS, PEP

"From shareholder unrest about Chairman & CEO Indra Nooyi's performance to market losses against Coca-Cola (KO), PepsiCo (PEP) has been a disappointment. Regrettably, the stock appears to have more room to fall given past performance. In light of this backdrop, I strongly recommend going long Coca-Cola to benefit from the outperformance. Dr. Pepper (DPS) is a speculative "buy" as it is near its 52-week high.
Source: Internal research. Note: PepsiCo's EPS over the past decade.

PepsiCo has been consistent in growing EPS over the years, but the results have not been strong enough. If you take a logarithmic regression of EPS over the past decade, you extrapolate 2016 EPS to be $5.55. Taking a PE multiple of 17x and multiplying by 17x yields a future stock price of $94.38. Discounting backwards by a low WACC of 8% yields a target price of $64.23 -- below the current valuation. The 3.1% dividend yield is also compromised by the uncomfortable financial position. A quick ratio of 0.8 and debt/equity ratio of 1.2 are unsettling.


Investors would be wise to then go with Coca-Cola, which offers a safe 2.7% dividend yield and is rated close around a "buy" on the Street. This top brand merits a premium to the market given its sustainability and solid consistent growth. EPS is expected to grow 8.2% annually over the next five years. That means a future stock price of $109.44 or a combined average return of 11.7% when factoring in dividend yields."


"...There are additional reasons why those seeking stability should back Coca-Cola. Performance, for example, has been predictable but still better-than-expected. Volatility is roughly half of the broader market. Management has executed time and time again while rightfully pursuing penetration in emerging markets. And, unlike PepsiCo, equity exceeds debt. Accordingly, I rate the stock a "strong buy.""



Tuesday, June 19, 2012

WAG's Pain is CVS' Gain

Rarely do we see a binary equity relationship defined as clearly as we have today.  The case could be made that the Boeing/EADS relationship is one such example, but these are companies located in different continents.  Well, today we see as close to a pure example of such a relationship in the US equity market. 

Wallgreen announced the purchase of European pharmacy chain Alliance Boots.  Have Wallgreen's ongoing difficulties with Express Scripts led them to change their strategy and go international?  It sure looks this way.  Does this signal capitulation to CVS Caremark in the U.S. market?  Well, at least Wallgreen got it for a discount since, well...it's Europe (and we all know that market is less than happy).  Right?  It does't look that way.  From Reuters: 

"The synergy numbers are very real," says GAMCO Investors analyst Jeff Jonas, highlighting verticals like drug procurement and Boots' beauty products. Still, Jonas calls the deal "defensive" and says that, as a result, Walgreens paid a full price of roughly 10-to-11 times Alliance Boots' expected earnings.

Additionally, there are questions about the valuation.  From Bloomberg:

The deal will lead to cost and revenue benefits across both companies of $100 million to $150 million in the first year and $1 billion by the end of 2016, according to the statement.
Walgreen, which was advised by Goldman Sachs Group Inc. (GS) and Lazard, forecast the transaction will add 23 cents to 27 cents a share to diluted earnings per share in the first year after completion of the initial investment, excluding one-time costs. Alliance Boots was advised by Centerview Partners.
Some investors are skeptical about the projections for additional per-share earnings next year, said Brian Sozzi, an independent analyst in New York.
“The market doesn’t believe the projections,” Sozzi said in a telephone interview. “There is big-time integration risk here putting together a giant U.S. pharmaceutical business with a giant U.K. pharmaceutical business.”
The U.S. drugstore owner has lined up $3.5 billion of short-term debt financing from Goldman Sachs and Bank of America Merrill Lynch to help fund the acquisition, according to a statement from KKR. Walgreen plans to replace the bridge facility with permanent financing at a later stage.
In any case, the outcome is that Wallgreen stock goes down and CVS Caremark goes up.  I would attribute much of Wallgreen's troubles to their defensive position which is the result of the long dragged out but seemingly successful merger of CVS Caremark.  For this reason, CVS remains a buy.  Like any announcement, investors must now wait and see.

Monday, June 18, 2012

Monday Morning Reads

Get reading...

The Big Picture - 10 Monday Reads

Seeking Alpha - Wall Street Breakfast

ZeroHedge - Daily US Opening

Positions Added on Wednesday/Thursday

I added the following positions last Wednesday and Thursday:



Ticker
Company
Price
Change%
Volume
Transaction
Date
Cost
Gain%
1
Kinder Morgan Management LLC
70.14
-0.44%
148,113
Buy
6/13/2012
70.3145
-0.25%
2
Berkshire Hathaway Inc.
82.2
0.59%
4,122,924
Buy
6/13/2012
80.43
2.20%
3
The Coca-Cola Company
75.87
0.17%
6,076,694
Buy
6/13/2012
74.6799
1.59%
4
CVS Caremark Corporation
45.41
-0.87%
5,134,378
Buy
6/14/2012
45.7416
-0.72%
Total
4 Stocks
-0.18%

0.53%


In subsequent posts this week I will review the investment decisions for these positions...stay tuned.